<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00486473</url>
  </required_header>
  <id_info>
    <org_study_id>MH 131</org_study_id>
    <nct_id>NCT00486473</nct_id>
  </id_info>
  <brief_title>Multihance Versus Magnevist in Breast MRI</brief_title>
  <acronym>DETECT</acronym>
  <official_title>Phase III Multicenter Double-Blind, Randomized, Crossover Study to Compare MultiHance With Magnevist in Contrast-enhanced Magnetic Resonance Imaging (MRI) of the Breast</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bracco Diagnostics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To show if one MRI contrast agent is better than another one in the diagnosis of malignant
      breast lesions compared to histopathology
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity in diagnosing breast lesions compared to histopathology results</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity, specificity, accuracy, PPV and NPV at region, breast and patient levels</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multihance</intervention_name>
    <description>0.5 Molar at a single dose injection</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnevist</intervention_name>
    <description>0.5M at a single dose injection</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provides written informed consent

          -  Female

          -  Age 18 years or older

          -  Suspicious or known breast lesion based on results from mammography or ultrasound

          -  Planned to undergo histological diagnosis of breast lesion by having a non surgical
             biopsy or breast surgery within 30 days after the MRI exam

        Exclusion Criteria:

          -  Body weight &gt; 100 kg

          -  Pregnant or lactating

          -  Server or end-stage organ failure

          -  Moderate to severe renal impairment

          -  Undergoing radiotherapy or completed radiotherapy in the last 18 months

          -  Chemotherapy within 6 months of the 1st MRI exam
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gianpaolo Pirovano, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bracco Dianostics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2007</study_first_submitted>
  <study_first_submitted_qc>June 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2007</study_first_posted>
  <last_update_submitted>July 14, 2010</last_update_submitted>
  <last_update_submitted_qc>July 14, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Gianpaolo Pirovano, M.D., Executive Director, Corporate Medical Development</name_title>
    <organization>Bracco Diagnostics, Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

